The EU has granted almost €4 million to the STARDUST project; a backronym for ‘in vivo optogeneticS, elecTrophysiology and phArmacology with an ultRasonically-powered DUST for Parkinson's Disease’.
STARDUST aims to provide an implantable ultrasonically powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device.
The main ambition is to develop a new technology platform that can be used to monitor and treat diseases, with an optional local drug delivery add-on beyond 2025.
The consortium is coordinated by researchers from Aarhus University in Denmark and involves partners from Germany, Belgium, France, Ireland, Finland and Brazil. At NERF, the Kloosterman lab will contribute to the development and testing of the STARDUST device.
In vivo optogeneticS, elecTrophysiology and phArmacology with an ultRasonically-powered DUST for Parkinson's Disease
From 2017-10-01 to 2021-09-30, ongoing H2020 project